Establishment Labs Holdings (ESTA) Aperçu de l'action
Establishment Labs Holdings Inc. est une entreprise de technologie médicale qui fabrique et commercialise des dispositifs médicaux pour les chirurgies esthétiques et reconstructives du sein en Europe, au Moyen-Orient, en Afrique, en Amérique latine, en Asie et aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 1/6 |
| Croissance future | 6/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour ESTA à partir de nos contrôles de risques.
ESTA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Establishment Labs Holdings Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$72.67 |
| Plus haut sur 52 semaines | US$97.59 |
| Plus bas sur 52 semaines | US$36.53 |
| Bêta | 1.09 |
| Variation sur 1 mois | -21.28% |
| Variation sur 3 mois | 0.041% |
| Variation sur 1 an | 78.73% |
| Variation sur 3 ans | 32.30% |
| Variation sur 5 ans | 1.18% |
| Évolution depuis l'introduction en bourse | 193.62% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Aug 20
ESTA: Q2 Execution And New Reconstruction Cycle Will Support 2026 Outlook
The updated Analyst Price Target for Establishment Labs Holdings changes from $95.33 to $102.44. Analysts point to recent price target increases from firms such as Citi, TD Cowen, Mizuho and BTIG, which they say reflect confidence in the Q2 report, the valuation after the recent pullback, and the upcoming reconstruction product cycle and U.S. launches.Article d’analyse • Aug 10
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$102
It's been a mediocre week for Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shareholders, with the stock dropping...Recent updates
Mise à jour du récit • Aug 20
ESTA: Q2 Execution And New Reconstruction Cycle Will Support 2026 Outlook
The updated Analyst Price Target for Establishment Labs Holdings changes from $95.33 to $102.44. Analysts point to recent price target increases from firms such as Citi, TD Cowen, Mizuho and BTIG, which they say reflect confidence in the Q2 report, the valuation after the recent pullback, and the upcoming reconstruction product cycle and U.S. launches.Article d’analyse • Aug 10
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$102
It's been a mediocre week for Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shareholders, with the stock dropping...
Mise à jour du récit • Aug 06
ESTA: Upcoming Earnings And Margin Outlook Will Support Repricing
Analysts have lifted their fair value estimate for Establishment Labs Holdings to $117 from $100, citing a lower assumed discount rate, a higher profit margin profile, and recent price target increases across the Street as support for the new target range. Analyst Commentary Recent Street research on Establishment Labs Holdings points to a more constructive tone heading into upcoming earnings updates.Mise à jour du récit • Jul 23
ESTA: Q2 Earnings Preview And 2026 Outlook Will Temper Sector Volatility
The analyst price target for Establishment Labs Holdings has been raised by $4.67 to reflect updated views on fair value and assumptions around revenue, profit margins and future P/E, as several firms recently lifted their targets into a Q2 earnings preview. Analyst Commentary Recent research on Establishment Labs Holdings points to a more constructive tone around the stock into Q2 earnings, with several firms lifting their price targets while still flagging sector level risks in medical devices.
Mise à jour du récit • Jul 08
ESTA: Index Additions And 2026 Guidance Will Support Measured Repricing
Analysts have modestly lifted their fair value estimate for Establishment Labs Holdings to $84, supported by a higher Street price target of $92 and updated assumptions around revenue growth, profit margins, and future P/E. Analyst Commentary Recent Street research on Establishment Labs Holdings points to a more measured stance, even as the official price targets cited are above the current fair value estimate.Mise à jour du récit • Jun 18
ESTA: Fair 2026 Outlook Will Balance Overdone Selloff And Execution Risks
Analysts have nudged their price target on Establishment Labs Holdings higher to about $90.67 from $89, citing what they view as an overdone selloff and updated views on fair value and future earnings multiples. Analyst Commentary Recent Street research on Establishment Labs Holdings highlights a mix of optimism and caution as analysts reassess what they view as an overdone selloff and revisit their valuation work.Mise à jour du récit • Jun 03
ESTA: Rebased Expectations And Raised 2026 Guidance Will Support Measured Repricing
Analysts have lifted their price target on Establishment Labs Holdings by $11 to $74, pointing to what they see as an overdone selloff and reaffirming that sector fundamentals in medical technology remain healthy despite recent volatility. Analyst Commentary Recent research updates on Establishment Labs Holdings highlight a mixed backdrop, with some analysts pointing to what they view as an overdone selloff while others trim expectations and flag risks around execution and valuation.Mise à jour du récit • May 17
ESTA: Raised 2026 Guidance And Profitability Will Support Bullish Repricing
Analysts have lifted their consolidated price target on Establishment Labs to $76.00, supported by recent research that cites updated Q4-driven models, sustained profitability, and reinforced confidence in upcoming US guidance. Analyst Commentary Street research around Establishment Labs Holdings has been active, with multiple firms updating their models following the latest Q4 results and guidance.Mise à jour du récit • Apr 29
ESTA: Mixed Research Views And 2026 Outlook Will Shape Earnings Profile
Narrative Update on Establishment Labs Holdings The updated analyst price target for Establishment Labs Holdings has shifted from about $75 to roughly $69, as analysts factor in slightly softer modeled revenue growth and profit margins, partly offset by a higher assumed future P/E and mixed recent price target moves across the Street. Analyst Commentary Recent Street research on Establishment Labs Holdings presents a mixed picture, with some more optimistic voices balancing out a set of cautious adjustments.Mise à jour du récit • Apr 14
ESTA: Sustained Adj EBITDA Profitability And US Guidance Will Support Repricing
Analysts have revised the price target for Establishment Labs Holdings to $100, reflecting updated views on discount rates, margins, and long term P/E assumptions following recent sector wide model adjustments and company specific Q4 and guidance commentary. Analyst Commentary Recent research coverage on Establishment Labs Holdings has centered on how the company’s Q4 results, guidance, and sector wide model resets feed into valuation frameworks, particularly around updated P/E assumptions and revised discount rates.Mise à jour du récit • Mar 31
ESTA: Sustained EBITDA Profitability And 2026 Guidance Will Support Stronger Outlook
Narrative Update on Establishment Labs Holdings The updated analyst price target of $89.00 for Establishment Labs Holdings, which held steady compared with the prior $89 level, reflects analysts balancing recent target increases tied to Q4 results and 2026 guidance with a sector wide recalibration in medical technology and a view among some that the recent selloff was unwarranted and overdone. Analyst Commentary Recent Street research on Establishment Labs Holdings highlights a mix of supportive and cautious views as analysts update their models following Q4 results, 2026 guidance and volatility across the medical technology group.Mise à jour du récit • Mar 17
ESTA: Sustained EBITDA Profitability And U S Guidance Will Support Stronger Outlook
Analysts have nudged the fair value estimate for Establishment Labs Holdings to $89.00, reflecting updated price targets across the Street that incorporate recent Q4 results, refreshed guidance, and sector wide medtech adjustments. Analyst Commentary Street research around Establishment Labs Holdings has shifted meaningfully following Q4 results and updated guidance, with a spread of targets from $74 to $100 helping anchor the new $89.00 fair value estimate.Mise à jour du récit • Mar 03
ESTA: Sustained Adj EBITDA Profitability And US Guidance Will Drive Repricing
Analysts have raised their average fair value estimate for Establishment Labs Holdings to $100 from $90, citing recent price target increases and updated models that reflect Q4 results, sustained Adj. EBITDA profitability, and a more constructive view on 2026 and US guidance.Mise à jour du récit • Feb 17
ESTA: 2025 Revenue Guidance And Margin Outlook Will Support Repricing
Analysts have maintained their $90.00 price target for Establishment Labs Holdings, citing updated assumptions that reflect a lower discount rate, modestly higher revenue growth and profit margin expectations, as well as a slightly reduced future P/E multiple. What's in the News The company issued preliminary revenue guidance for the fourth quarter of 2025, with unaudited revenue expected between $64.0 million and $65.0 million, including $17.0 million to $17.5 million from Motiva sales in the United States (Key Developments).Mise à jour du récit • Feb 03
ESTA: Positive EBITDA And U S Expansion Will Support Stronger Forward Outlook
Narrative Update on Establishment Labs Holdings The analyst price target for Establishment Labs Holdings has been lifted from about US$79.67 to roughly US$83.25, as analysts point to recent Q3 revenue and EBITDA beats, an outlook for 2025 revenue above the prior guidance midpoint, and expectations for stronger Motiva sales as key drivers of their updated assumptions. Analyst Commentary Recent research notes give you a clearer picture of how the Street is thinking about Establishment Labs Holdings after its latest Q3 update and guidance commentary.Mise à jour du récit • Jan 20
ESTA: First Positive EBITDA And 2025 Outlook Will Support Repricing
Analysts have raised their price target on Establishment Labs Holdings to an implied fair value of $90, up from $70, citing better than expected Q3 results, the first quarter of positive EBITDA, and increased confidence in management's updated revenue expectations for 2025. Analyst Commentary Bullish analysts are framing the recent Q3 report as a key proof point for Establishment Labs Holdings, highlighting that revenue and adjusted EBITDA figures were ahead of prior consensus expectations.Mise à jour du récit • Jan 06
ESTA: Q3 Profitability And U.S. Expansion Will Reshape Earnings Profile
Narrative Update The analyst fair value estimate for Establishment Labs Holdings has shifted from US$40.00 to US$75.00. Analysts attributed this change to stronger than expected Q3 revenue, the company’s first quarter of positive EBITDA, increased 2025 revenue expectations, and greater conviction in the U.S. Motiva sales potential as key drivers of their higher price targets.Article d’analyse • Jan 02
Revenues Not Telling The Story For Establishment Labs Holdings Inc. (NASDAQ:ESTA)
Establishment Labs Holdings Inc.'s ( NASDAQ:ESTA ) price-to-sales (or "P/S") ratio of 11.1x may look like a poor...Mise à jour du récit • Dec 20
ESTA: Positive EBITDA And U S Expansion Will Support Measured Forward Outlook
Analysts have modestly increased their price target for Establishment Labs Holdings to approximately $80 per share from about $74, citing stronger than expected Q3 results, the company's first quarter of positive EBITDA, as well as growing confidence in sustained revenue growth and U.S. Motiva sales expansion. Analyst Commentary Street research following the Q3 print reflects a predominantly constructive stance on Establishment Labs, with analysts highlighting both upside drivers and lingering risks that could influence valuation and execution.Mise à jour du récit • Dec 05
ESTA: Positive EBITDA And U S Expansion Will Support Balanced Outlook
Analysts have lifted their price target on Establishment Labs Holdings, increasing fair value estimates to about $74 from roughly $71, supported by stronger than expected Q3 results, the company’s first positive EBITDA, and raised 2025 revenue expectations. Analyst Commentary Recent research notes highlight a generally constructive stance on Establishment Labs Holdings, with multiple firms lifting price targets following the latest Q3 results and updated 2025 guidance.Mise à jour du récit • Nov 21
ESTA: Continued U S Sales Gains And Improved Margins Will Support Balanced Outlook
Analysts have raised their price target for Establishment Labs Holdings from $62.22 to $71.33 per share, reflecting continued outperformance in Q3 results, improving profit margins, and increased confidence in future revenue growth. Analyst Commentary Analysts have responded to Establishment Labs Holdings' recent performance with revised outlooks, highlighting both areas of strength and potential challenges for the company.Article d’analyse • Nov 08
US$62.22 - That's What Analysts Think Establishment Labs Holdings Inc. (NASDAQ:ESTA) Is Worth After These Results
A week ago, Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) came out with a strong set of third-quarter numbers that...Mise à jour du récit • Nov 07
ESTA: Positive Earnings And U S Market Expansion Will Drive Balanced Outlook
The analyst price target for Establishment Labs Holdings has increased from $55.44 to $62.22 per share. Analysts cite strong Q3 results, improved profit margins, and raised revenue guidance as key drivers of this upward revision.Article d’analyse • Jul 22
We Think Establishment Labs Holdings (NASDAQ:ESTA) Has A Fair Chunk Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Nouveau récit • May 28
Minimally Invasive Procedures Will Expand US And Global Aesthetic Markets
Increasing demand for minimally invasive cosmetic breast procedures and strong U.S. market performance are driving revenue growth and higher margins.Article d’analyse • Apr 22
The Price Is Right For Establishment Labs Holdings Inc. (NASDAQ:ESTA) Even After Diving 26%
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shares have had a horrible month, losing 26% after a relatively good...Article d’analyse • Apr 09
Here's Why Establishment Labs Holdings (NASDAQ:ESTA) Can Afford Some Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Mar 19
What Is Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Share Price Doing?
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ), might not be a large cap stock, but it received a lot of attention...Article d’analyse • Mar 01
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
The investors in Establishment Labs Holdings Inc. 's ( NASDAQ:ESTA ) will be rubbing their hands together with glee...Article d’analyse • Feb 28
After Leaping 29% Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Are Not Flying Under The Radar
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shareholders are no doubt pleased to see that the share price has...Article d’analyse • Jan 14
Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Establishment Labs Holdings Inc. ( NASDAQ:ESTA ) shares have had a horrible month, losing 27% after a relatively good...Article d’analyse • Nov 25
Is Establishment Labs Holdings Inc. (NASDAQ:ESTA) Trading At A 21% Discount?
Key Insights The projected fair value for Establishment Labs Holdings is US$54.78 based on 2 Stage Free Cash Flow to...Rendement pour les actionnaires
| ESTA | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | -5.2% | 1.5% | -1.2% |
| 1Y | 78.7% | -11.6% | 18.3% |
Rendement vs Industrie: ESTA a dépassé le secteur US Medical Equipment qui a rapporté -11.6 % au cours de l'année écoulée.
Rendement vs marché: ESTA a dépassé le marché US qui a rapporté 18.3 % au cours de l'année écoulée.
Volatilité des prix
| ESTA volatility | |
|---|---|
| ESTA Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: ESTA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de ESTA ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2004 | 1,004 | Fillipo Caldini | www.establishmentlabs.com |
Establishment Labs Holdings Inc. est une entreprise de technologie médicale qui fabrique et commercialise des dispositifs médicaux pour les chirurgies esthétiques et reconstructives du sein en Europe, au Moyen-Orient, en Afrique, en Amérique latine, en Asie et aux États-Unis. La société propose des implants mammaires remplis de gel de silicone sous la marque Motiva Implants. Elle fournit également des expanseurs de tissus mammaires.
Establishment Labs Holdings Inc. Résumé des fondamentaux
| ESTA statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$2.17b |
| Bénéfices(TTM) | -US$38.89m |
| Recettes(TTM) | US$245.82m |
8.8x
Ratio P/S-55.7x
Ratio P/ELe site ESTA est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ESTA compte de résultat (TTM) | |
|---|---|
| Recettes | US$245.82m |
| Coût des recettes | US$72.54m |
| Marge brute | US$173.27m |
| Autres dépenses | US$212.17m |
| Les revenus | -US$38.89m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.30 |
| Marge brute | 70.49% |
| Marge bénéficiaire nette | -15.82% |
| Ratio dettes/capitaux propres | 1,211.2% |
Quelles ont été les performances à long terme de ESTA?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/24 11:35 |
| Cours de l'action en fin de journée | 2026/08/21 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Establishment Labs Holdings Inc. est couverte par 14 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Neil Chatterji | B. Riley Securities, Inc. |
| Sam Eiber | BTIG |
| Michael Gorman | BTIG |